PMID- 36840440
OWN - NLM
STAT- MEDLINE
DCOM- 20230412
LR  - 20230624
IS  - 1537-2995 (Electronic)
IS  - 0041-1132 (Linking)
VI  - 63
IP  - 4
DP  - 2023 Apr
TI  - Risk of HLA antibody generation after receipt of Mirasol versus standard 
      platelets in the MIPLATE randomized trial.
PG  - 791-797
LID - 10.1111/trf.17286 [doi]
AB  - BACKGROUND: Human leukocyte antigen (HLA) alloimmunization can occur after 
      platelet transfusion. These antibodies can complicate future platelet 
      transfusions or organ transplantation. Animal data suggest that Mirasol pathogen 
      reduction treatment (PRT) can prevent alloimmunization after transfusion. STUDY 
      DESIGN AND METHODS: The MIPLATE trial enrolled 330 of a planned 660 participants 
      with hematological malignancies at risk for grade 2 or greater bleeding. The 
      study was halted early for futility after a planned interim analysis. 
      Participants were randomized to receive PRT versus standard control platelets. 
      Serum samples were collected from participants at baseline (pretransfusion), 
      weekly for the first 4 weeks, then at days 42 and 56. HLA antibody levels were 
      determined using a commercial multianalyte bead-based assay. HLA antibody levels 
      were analyzed using low, medium, and high cutoffs based on prior studies. 
      RESULTS: The rate of alloimmunization was low in both arms of the study, 
      particularly at the high HLA antibody cutoff (total of 6 of 277 subjects at risk, 
      or 2.2%). The risk of alloimmunization did not differ between study arms, nor did 
      the risk of immune refractoriness to platelet transfusion. CONCLUSIONS: The data 
      do not support the conclusion that Mirasol exerted a protective effect against 
      alloimmunization after platelet transfusion in the MIPLATE trial.
CI  - (c) 2023 AABB.
FAU - Kaidarova, Zhanna
AU  - Kaidarova Z
AD  - Vitalant Research Institute, San Francisco, California, USA.
FAU - Di Germanio, Clara
AU  - Di Germanio C
AUID- ORCID: 0000-0002-6047-211X
AD  - Vitalant Research Institute, San Francisco, California, USA.
AD  - Department of Laboratory Medicine, University of California, San Francisco, 
      California, USA.
FAU - Custer, Brian
AU  - Custer B
AUID- ORCID: 0000-0001-6251-366X
AD  - Vitalant Research Institute, San Francisco, California, USA.
AD  - Department of Laboratory Medicine, University of California, San Francisco, 
      California, USA.
FAU - Norris, Philip J
AU  - Norris PJ
AUID- ORCID: 0000-0003-0526-2088
AD  - Vitalant Research Institute, San Francisco, California, USA.
AD  - Department of Laboratory Medicine, University of California, San Francisco, 
      California, USA.
AD  - Department of Medicine, University of California, San Francisco, California, USA.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20230225
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - 0 (Isoantibodies)
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Animals
MH  - Humans
MH  - *Isoantibodies
MH  - *Blood Platelets
MH  - Platelet Transfusion/adverse effects
MH  - HLA Antigens
MH  - Histocompatibility Antigens Class I
OTO - NOTNLM
OT  - alloimmunization
OT  - pathogen reduction
OT  - platelets
EDAT- 2023/02/26 06:00
MHDA- 2023/04/12 06:42
CRDT- 2023/02/25 04:49
PHST- 2023/01/06 00:00 [revised]
PHST- 2022/10/18 00:00 [received]
PHST- 2023/01/30 00:00 [accepted]
PHST- 2023/04/12 06:42 [medline]
PHST- 2023/02/26 06:00 [pubmed]
PHST- 2023/02/25 04:49 [entrez]
AID - 10.1111/trf.17286 [doi]
PST - ppublish
SO  - Transfusion. 2023 Apr;63(4):791-797. doi: 10.1111/trf.17286. Epub 2023 Feb 25.